ADB-FUBICA

APICA is an indole based drug that acts as a potent agonist for the cannabinoid receptors.

AB-FUBINACA (AMB-FUBINACA) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with K_i values of 0.9 nM at CB₁ and 23.2 nM at CB₂ and EC₅₀ values of 1.8 nM at CB₁ and 3.2 nM at CB₂. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported.

AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.

ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. ADBICA is a potent agonist of the CB₁ receptor and CB₂ receptor with an EC₅₀ value of 0.69 nM and 1.8 nM respectively.

ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.

AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor (K_i = 0.78 nM) and CB₂ receptor (K_i = 0.45 nM) and fully substitutes for Δ⁹-THC in rat discrimination studies, while being 16x more potent. Continuing the trend seen in other cannabinoids of this generation, such as AB-FUBINACA and AB-PINACA, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue.

ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB₁ receptor and CB₂ receptor with EC₅₀ values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBINACA, this compound contains an amino acid residue of tert-leucine.

5F-ADB (also known as MDMB-5F-PINACA and 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products and has been sold online as a designer drug. 5F-ADB is a potent agonist of the CB₁ receptor, though it is unclear whether it is selective for this target. 5F-ADB was first identified in November 2014 from post-mortem samples taken from an individual who had died after using a product containing this substance. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. 5F-ADB is believed to be extremely potent based on the very low levels detected in tissue samples, and appears to be significantly more toxic than earlier synthetic cannabinoid drugs that had previously been sold.

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor with a binding affinity of K_i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.

5F-AB-PINACA is an indazole-based synthetic cannabinoid that is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication, and has been sold online as a designer drug.

MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with K_i values of 1.14 nM at CB₁ and 0.1228 nM at CB₂ and EC₅₀ values of 0.2668 nM at CB₁ and 0.1411 nM at CB₂, and has been sold online as a designer drug. Its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB₁ receptor (K_i = 0.14 nM, EC₅₀ = 2.42 nM). The structure of MDMB-FUBINACA contains the amino acid, 3-methylvaline or tert-leucine methyl ester.

PX-2 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It contains a phenylalanine amino acid amide as part of its structure.

APP-FUBINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. Pharmacological testing showed APP-FUBINACA to have only moderate affinity for the CB₁ receptor, with a Ki of 708 nM, while its EC₅₀ was not tested. It contains a phenylalanine amino acid residue in its structure.

5F-ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB₁ receptor and CB₂ receptor with EC₅₀ values of 0.24 nM and 2.1 nM respectively.

AB-FUBICA is a drug that acts as a potent agonist for the cannabinoid receptors, with EC₅₀ values of 21 nM at CB₁ and 15 nM at CB₂.

AB-PICA is a potent agonist for the CB₁ receptor (EC₅₀ = 12 nM) and CB₂ receptor (EC₅₀ = 12 nM).

5F-ADBICA (also known as 5F-ADB-PICA) is an indole-based synthetic cannabinoid that is a potent agonist at CB₁ receptors and CB₂ receptors with EC₅₀ values of 0.77 nM and 1.2 nM respectively.

MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB₁ receptor and has been sold online as a designer drug.

ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB₁ receptor with a binding affinity (K_i) of 0.33 nM and an EC₅₀ of 14.7 nM.